Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. uri icon

authors

  • Patorno, Elisabetta
  • Kim, Seoyoung C
  • Htoo, Phyo T
  • Glynn, Robert J
  • Schneeweiss, Sebastian
  • Wexler, Deborah J
  • Pawar, Ajinkya
  • Lily G Bessette, MS
  • Chin, Kristyn
  • Everett, Brendan M

publication date

  • September 28, 2021